DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
0h man, I totally hear you. It's good to be critical and watchful in the OTC market. Nine times out of ten, we are all are encountering junk, trying to scrap some shabby profits off a pump and dump and becoming more conditioned along the way to expect more of the same with the next ticker we come across. Yet, that leaves one time out of ten where a stock is legitimate, capable of amazing feats, not only in terms of pps but also in terms of brining a product through a very stringent regulatory process and human trials, to the marketplace. In this case, I believe Propanc will succeed not only because of their product, but because of the people of Propanc.
PPCH is trading so cheap because it hasn't generated any real revenue. But, if you think about it, this current pps is not really that cheap and the share price reflects all the steps Propanc has taken to get to the FDA approval meeting, including patent licensing, a huge financing arrangement for 5 million that feel through, forming solid academic partnerships, and before that, bringing on to their scientific board, some of the best cancer researchers and drug developers in the world. It is currently trading on pure potential, but the stock market is a forward moving mechanism, and based on my DD, this potential will be realized as Propanc is poised for success. Do what you will with your shares and do your own DD, I am not trying to convince you that PPCH is gonna be a big winner$$$
Thanks Jack and a good weekend to you too!
Victory indeed. A triumphant close.
Thanks for that Jack. I saw your bid--wondered if it was you:)
Hey nh2nc, You are very welcome! Glad to see you are still in it here. Buckle up and stay strong through the ups and downs. In the end, it's Propanc's destiny to make it big, IMO and nobody can stop that. Propanc has all the right qualities that define success: Intelligent/Experienced/Altruistic People + Quality/Innovative/Imperative Product! = Success
Welcome subaru. You've made as good an entry as any at this juncture. Buckle your seatbelt! GO PPCH$$$$
FDA will give IND APPROVAL. Gonna BE BIG FOR PPCH. PR coming soon.
Gonna make a huge run. FDA approval coming. C'mon, this is Propanc. PRP on marketplace sooner than you think!
Clinical Trials Scheduled for 2015. Furthermore, Propanc has completed limited human testing on their lead product, PRP, with positive results: "In limited human testing as outlined earlier, supplemented by laboratory research at the Universities of Bath and Granada on the mechanism of action of the proenzyme mixture, evidence has been obtained which suggests PRP may be effective against a range of solid tumors."
insert-text-here
Successful PPCH PRP Drug Patents in US, Europe, and South Africa
http://ipfrontline.com/2014/05/propanc-files-patent-application-for-new-cancer-treatment/
The academic partnerships are HUGE! They give PPCH so much credibility. After you sent me the link, I searched "propanc" on the University of Bath website and they list all the times Propanc made it in the news. PPCH has very promising past and even more promising future.
Propanc files patent application for new cancer treatment
insert-text-here
THE EXCLUSIVE LICENSES AND DRUG PATENTS ARE THE FABRIC OF PPCH.
GREAT LOADING PPS THIS IS GONNA FLY $$$
AND THOSE HUMAN TRIALS ARE FAST-TRACKED! POTENTIAL ODD. THINK JAZZ PHARMACEUTICALS.
PR on successful animal studies is gonna help in the coming weeks
Over .02 it is!
Watching and holding and buying and waiting!
GOO PPCH!!
Propanc's Experetise! This Ain't No Scam
Mr James Nathanielsz Chief Executive Officer
Director & C.E.O, Oct ‘07.
15 yrs. experience in R&D, Manufacturing & Distribution, including 10 yrs. in oncology
Bachelor of Applied Science (Biochemistry/Applied Chemistry) & Master of Entrepreneurship & Innovation, Swinburne University, Melbourne, Australia.
Dr Julian Kenyon Chief Scientific Officer
Co-Founder & Director, Feb ‘08.
Medical Director of the Dove Clinic for Integrated Medicine, UK, since 2000.
Bachelor of Medicine & Surgery & Doctor of Medicine , University of Liverpool.
Primary Fellow of the Royal College of Surgeons, Edinburgh for over 40 years.
Prof. Klaus Kutz Chief Medical Officer
15 yrs. experience as consultant in Clinical Pharmacology & Safety in oncology.
12 yrs. experience Head of Clinical Pharmacology in 2 multinational pharma companies.
Specialist for Internal Medicine, Gastroenterology & Clinical Pharmacology.
Professor of Medicine, University of Bonn, Germany.
Propanc May Go for ODD for PRP: HUGE!
Potential ODD for Propanc
According to Professor Klaus Kutz, “Once we have assessed and identified the most effective dose in animals, we plan to meet with the FDA (Food and Drug Administration), to discuss and agree upon the planned formal preclinical program to support an Investigational New Drug Application (IND) to commence human trials in 2015," said Professor Klaus Kutz, Chief Medical Officer at Propanc Health Group. "Depending on the final indication selected for our initial patient trials, we may also seek Orphan Drug Designation for our treatment given the novelty of our proenzyme formulation and depending on the size of the target patient population we propose for trials."[color=red][/color]
So what’s the big deal about ODD?
“The industry has rushed to develop orphan drugs in recent years because they cost their developers less to put through clinical trials, and command higher prices when they do launch. Trial sizes are naturally smaller than for diseases with large populations, and the lack of alternative treatments give orphan agents an advantage when up for regulatory review. Tax incentives reduce development costs further. And when orphan drugs do reach the market, on average their cost per patient is six times that of non-orphan drugs, a clear indication of their pricing power.”
Or as Stephen Rattner of NY Times put it, referring to the monstrous climb in the PPS of Jazz Pharmaceuticals, “to get drug developers to focus on these relatively small pools of patients, the federal government offers inducements like a 50 percent research-and-development tax credit as well as a longer period of market exclusivity (seven years after Food and Drug Administration approval, rather than the typical five). These long monopolies often give orphan drug makers a free hand to raise prices.”
[url]opinionator.blogs.nytimes.com/2013/06/30/the-orphan-jackpot/
[/url][tag]insert-text-here[/tag]
Other facts about ODD:
1. Worldwide orphan drug sales forecast to total 176 billion, almost double overall prescription market growth (excluding generics).
2. Orphan drugs set to be 19.1% of worldwide prescription sales by 2020 (excluding generics)
3. Median cost per patient differential 19 times higher for orphan drugs compared to non-orphan
4. Bristol-Myers Squibb set to climb to number one position in orphan drug sales to 2020
5. Phase III orphan drug development cost half that of non-orphan; potentially a quarter with US tax breaks
6. Phase III drug development time for orphan is no quicker than non-orphan
7. Orphan drug FDA approval time 10 months vs. 13 months for non-orphan
8. Expected return on investment of phase III/ filed orphan drugs 1.89 times greater than non-orphan drugs
See the link below for full Evaluation Report of 2014 Orphan Drugs:
insert-text-here
P.S. Image searching stock charts when ODD is announced show immediate blast-offs. Check it out.
Propanc's Professor Klaus Kutz, M.D., CMO
He will bring PRP through successful human trials, IMO.
Professor Kutz has ten years of experience as independent consultant in Clinical Pharmacology and Safety for pharmaceutical companies and clinical research organizations. His specialty over the last six years is Oncology, including preparation of multiple NDAs and INDs for small and medium sized pharmaceutical companies. He has prepared, organized and reported clinical Phase I studies in oncology and Phase II studies in different cancer indications (prostate, gastric, ovarian, small cell lung cancer) and Non-Hodgkin Lymphomas.
Professor Kutz has more than 12 years experience as Head of Clinical Pharmacology with world-wide responsibilities for Phase I and Clinical Pharmacokinetics in two internationally operating pharmaceutical companies, setting up and restructuring international Clinical Pharmacology departments. His achievements include the successful world-wide registration of multiple important Sandoz’ compounds by preparation of multiple NDAs (New Drug Applications) and Expert reports (including Written Summary), as well as the preparation of multiple INDs (Investigational New Drug Applications) for Sandoz Pharma Ltd and Sanofi Research. A specialist for Internal Medicine, Gastroenterology, and Clinical Pharmacology, he is also Professor of Medicine at the University of Bonn, Germany.
John Smythe of Propanc's Scientific Advisory Board
He built the oncology department at University of Edinburgh over the past 30 years. This guy will see PRP all the way through to licensing with big Pharma or Propanc's own share of the marketplace. Can't wait to see.
PPCH is gonna take off.
Video: John Smythe on his book on ecancer tv
insert-text-here
VERY NICE ENTRY HERE...DONT MISS IT
NEW NEWS WILL BE OUT SOON
GONNA BE BIG FOR PPCH
THIS PPS WILL BE LONG GONE IN ONE MONTH. BUY, BUY, BUY
PPCH's PRP WILL GO TO MARKET
IF YOU KNOW YOUR SCIENCE, YOU WOULD ALSO KNOW THIS IS TRUE
THIS IS JUST THE BEGINNING....FAST TRACK TO FDA APPROVAL
THE PEOPLE HAVE AWOKE!
Nice pick for Wednesday! .1378. Love it. Last after hours trade is already close to .025.
The people and product of PPCH will revolutionize the treatment of cancer. The scientific board of Propanc is A++. Check these guys out, read their CV's. They are ready to save millions of lives, and make a $ or two along the way :)
Just like that too. This stock hit it's 52 week high on licensing agreements. Wait for human trials and then FDA approval = $$$$. The people and product of PPCH are worth well over silver. Let's see dollars$$$$
Agreed! The movement and action today, though not the pps (yet!), reflects the true value of PPCH.
Congrats Jack$$$$$$
A dime it is! And then up and up. Imagine the PPS with successful FDA; I wouldn't be surprised if PPCH gets orphan drug designation. We could be in human trials by the summer. The valuation is inestimable IMO. Dollars+.
PPCH$$$$$$$$$$
WORKING TODAY! WOW. STILL HOLDING HERE. POP THE BUBBLIES.
Wish I could celebrate together...it was a journey. Looking forward to that long awaited .05 and up and up. Cheers.
Good Press Gonna Be Big for PPCH$$
Suppose we'll just all have to wait and see....
.01 is near..
She's gonna climb....slow now....faster as news approaches...and then up and up
Gonna have to hit the ask if you want in at this point
Bid at .0032 and Ask at .0043. Value is returning...